BENSALEM, Pa., Jan. 10, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ASTRAZENECA PLC (AZN), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE FEBRUARY 21, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.Contact the Law Offices of ...

NEW YORK, Jan. 10, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AstraZeneca investors who were adversely affected by alleged securities fraud between February 23, 2022 and December 17, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/astrazeneca-plc-lawsuit ...

As we enter 2025, many growth stocks are trading at high valuations and could be running out of room to rise in the near term. For long-term investors, now may be a good time to reevaluate the contents of your portfolio to see if it's worth potentially selling off some of your recent high performers and swapping in some cheaper growth stocks instead. By doing so, you could set yourself up for some better gains for not just this year but the long term as well.Three growth stocks that look particularly cheap ...

NEW YORK, Jan. 9, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN).Shareholders who purchased shares of AZN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/astrazeneca-plc-loss-submission-form-2/?id=121486&from=4CLASS PERIOD: February 23, 2022 to D ...

In the latest trading session, Astrazeneca (AZN) closed at $66.58, marking a -0.09% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.16%. Elsewhere, the Dow saw an upswing of 0.25%, while the tech-heavy Nasdaq depreciated by 0.06%.The the stock of pharmaceutical has fallen by 0.8% in the past month, leading the Medical sector's loss of 5.77% and the S&P 500's loss of 2.8%.Investors will be eagerly watching for the performance of Astrazeneca in its upcoming earning ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...

NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN). Shareholders who purchased shares of AZN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/astrazeneca-plc-loss-submission-form-2/?id=120892&from=3  CLASS PERIOD: February 23, ...

Johnson & Johnson on Tuesday said its lung cancer regimen keeps people alive for at least a year longer than AstraZeneca's Tagrisso, the go-to drug for a certain type of lung cancer.J&J in a statement said its drugs – Rybrevant and Lazcluze – showed a statistically significant and clinically meaningful improvement to survival relative to Tagrisso in a pivotal trial. The company expects the benefit to be at least a year and possibly longer, J&J executives said in an interview. The company plans to present th ...

NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AstraZeneca investors who were adversely affected by alleged securities fraud between February 23, 2022 and December 17, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/astrazeneca-plc-lawsuit- ...

NEW YORK, Jan. 6, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, both dates inclusive (the "Class Period"), of the February 21, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.So what: If you purchased AstraZeneca securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or c ...